KROS (Keros Therapeutics) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KROS Keros Therapeutics Inc KROS
41 GF Score
Price $10.64
GF Value $5.45
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Keros Therapeutics Short-term investments?

Short-term investments only applies to insurance companies.

KROS
41GF Score
Keros Therapeutics Inc KROS
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Keros Therapeutics (KROS) Overvalued in 2026?

Based on GuruFocus' analysis, Keros Therapeutics stock appears to be overvalued. The current stock price of $10.64 is trading 95.2% above its estimated GF Value™ of $5.45. GuruFocus considers Keros Therapeutics to be Significantly Overvalued.

Key valuation signals for KROS:

  • Short-term investments:
  • GF Value™: $5.45 vs. price of $10.64 (95.2% above fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the KROS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Keros Therapeutics Business Description

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
41GF Score

Get the complete analysis for KROS

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.64
Price
$5.45
GF Value